Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845445 | 0.93 | CA2 (0.44) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL16819975 | 0.93 | CA2 (0.44) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL18919029 | 0.93 | CA2 (0.44) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL16845529 | 0.85 | MAPT (0.46) | CA2CA1CA9CA12HTT | |
| SCHEMBL16820019 | 0.85 | MAPT (0.46) | CA2CA1CA9CA12HTT | |
| SCHEMBL16845450 | 0.85 | HTT (0.52) | SLC9A1HTT | |
| SCHEMBL16819981 | 0.84 | POLB (0.43) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL16819950 | 0.84 | CA2 (0.44) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL16819942 | 0.84 | POLB (0.43) | CA2SOS1CA1CA9CA12 | |
| SCHEMBL18919095 | 0.81 | CA1 (0.54) | CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | MERCK SHARP & DOHME CORP. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | CHRNA7, CHRNA5, CHRNA6 | CA2 2747/4885SOS1 4309/4885CA1 1704/4885 |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | CHRNA7, CHRNA6, CHRNA5 | CA2 2752/4885SOS1 4266/4885CA1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.